




may be found in a variety of clinical settings. Its diagnosis
and classification depend on histopathology. It is not a
common disease in Caucasians. The incidence has been
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ABSTRACT
Membranoproliferative glomerulonephritis (MPGN) is not a common disease. There are few studies
in China, especially for treatment and prognosis. We reviewed the clinical and pathological features
of 51 patients who were diagnosed to have primary idiopathic MPGN. Most patients presented
with hematuria, proteinuria, or nephrotic syndrome. Almost half of the patients had hypertension
and impaired renal function at presentation. Patients with type I MPGN, renal vascular disease, or
tubulointerstitial abnormality in the renal biopsy specimens frequently presented with hypertension
and renal impairment. Patients with type III MPGN often presented with nephrotic syndrome. In
general, children had less severe disease than adults did. Patients were followed for an average of
9.5 years (ranged from 9 months to 26 years). Five patients developed end-stage renal failure
during follow-up (3 to 25 years after initial presentation), four patients died during the follow-up
period. There was a beneficial effect of steroid therapy, with or without systemic anticoagulation
(urokinase, heparin, followed by warfarin and dipyridamole). Immunosuppressive treatment
commonly reduced proteinuria and improved renal function. In summary, MPGN is an aggressive
disease with poor long-term prognosis. Steroid therapy, with or without anticoagulants, may have
a beneficial effect.
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decreasing (1,2). The incidence of MPGN varies between
10.6% and 13.8% of all glomerulonephritis (GN) in
China (3,4). The pathogenesis of MPGN is unknown (5).
Patients of MPGN have a poor prognosis, and no
treatment has been proved effective. There are very few
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prednisone together with urokinase 20000 unit/day, and
heparin 50 mg/day to 70 mg/day subcutaneously for 4
weeks, and then dipyridamole 75 mg/day orally and
warfarin 2.5 mg/day for at least 4 weeks. International
normalized ratio (INR) was monitored to keep below
3.0. Five patients received prednisone, anticoagulant, and
cyclophosphamide 100 mg daily intravenously and
indomethacin 12.5 mg thrice daily orally for 1 month.
The total dosage of cyclophosphamide give ranged from
2 g to 4 g.
Statistical analysis
All data were expressed as mean +standard error of mean
(SE) unless otherwise specified. Characteristics between
groups were performed by Chi-square test, Student's t-
test, and one-way analysis of variance (ANOVA).
P values less than 0.05 was considered significant. All
probabilities were two-tailed.
RESULTS
Of the 51 patients, 29 were males, and 22 females. Their
age at presentation was 28.8 ±14.5 years. In all cases,
light microscopy revealed a diffuse proliferative GN with
thickening of the glomerular capillary walls, increased
in mesangial cells and matrix, and a lobulated appearance
of the glomerulus. Immunofluorescence studies were
available for 45 biopsies. The result was shown in
table 1. Twenty-one specimens were examined by
electron microscopy. In 14 specimens, subendothelial
Table 1.  Immunofluorescence study of 45 cases.
Positive
IgG IgM IgA C3 All All negative
No. of cases 28 32 22 29 15 6
(%)  (61.8%) (71.4%) (48.6%) (63.6%) (34.3%) (14.3%)
Table 2.  Summary of clinical features or presentation.
Clinical features No. of cases %
Preceded by upper respiratory tract infection 17 33.3%
Edema 41 80.4%
Macroscopic hematuria 11 21.6%
Microscopic hematuria 27 52.9%
Nephrotic syndrome 27 52.9%
Hypertension 25 49.0%
Renal impairment 27 52.9%
Anemia 24 47.1%
Hyperlipidemia 31 60.9%
Depressed serum C3 25 49.0%
Depressed serum C50 11 21.6%
Increased in CIC 34  66.7%
Hypertension = Blood pressure > 140/90 mmHg; Renal impairment = Serum creatinine > 120 µmol/L; Anemia = Hemoglobin
< 12 g/dL (male) or 11 g/dL (female); CIC = Circulating immune complexes
studies of MPGN in China, especially for treatment and
prognosis. In this paper, we present data on 51 MPGN
patients who have been followed for an average of 9.5
years. Their clinical, pathological features and response
to therapy are discussed.
PATIENTS AND METHODS
We identified 51 patients with renal biopsy between 1979
and 1995 that confirmed a diagnosis of idiopathic MPGN.
Secondary causes, such as systemic lupus erythematosus,
were excluded. All renal biopsy tissues were
examined by light microscopy, 45 were examined by
immunofluorescence, including IgG, IgA, IgM, C3,
HBsAg, and 21 specimens were examined by electron
microscopy. Pathologic criteria of glomerular disease
by WHO classification in 1982 were used (6).
Tubulointerstitial abnormality were classified
semiquantitatively into either mild or serious: mild
denoted few tubules atrophy or hypertrophy, and less
then 25% focal interstitial infiltration and fibrosis; serious
denoted significant tubules atrophy or hypertrophy, or
more than 25% interstitial infiltration and fibrosis. Vessel
lesions including arteriole intimal fibrosis or arteriole
hyaline degeneration were also scored.
Eight patients received no immunosuppressive therapy
or anticoagulant. Thirteen patients were treated with
prednisone alone, with a starting dosage of 30 mg/day
to 60 mg/day for at least 8 weeks, 25 patients received
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and mesangial deposits could be seen, confirming type I
MPGN. In seven specimens, there were subendothelial,
subepithelial and mesangial deposits, confirming type
III MPGN. There has no case of type II MPGN identified
in our series. Clinical features at presentation were
summarized in table 2.
The clinical features of type I MPGN and type III MPGN
were compared and summarized in table 3. We found
that blood pressure in cases of type I was slightly higher
than that in type III MPGN. Initial creatinine clearance
was lower in type I than that in type III, and proteinuria
was more serious in type III than that in type I. Nephrotic
syndrome was found to be more in type III patients than
that in type I patients (85.7% vs 21.4 % cases, p < 0.05).
Clinical features of adults and children (age less than 15
years) were compared and shown in table 4. Adults
frequently presented with hypertension and renal
impairment, while children frequently presented with
macroscopic hematuria. The relationship of clinical
features with renal vascular abnormalities and
tubulointerstitial abnormalities were summarized in table
5 and table 6 respectively. Patients that presented with
hypertension and renal function impairment generally
had more severe renal vascular and tubulointerstitial
abnormalities.
Twenty-five patients (49.0%) had low serum C3 level
and 11 patients (21.6%) had low serum CH50
concentration at diagnosis. We found that serum
complement level fluctuate with time, and returned to
normal in six patients. We found no relationship between
complement levels and clinical presentation, disease
severity and response to treatment (details not shown).
In addition, immunofluorescence appearance did not
correlate with clinical features and disease severity.
Patients with hypocomplementemia tended to have
positive C3 staining in immunofluorescence study
(details not shown).
Table 3.  Comparison of clinical features in type I and type III MPGN.
Type I Type III p value
No. of cases 14 7
Urine protein (g/day) 3.21 ±2.77 6.60 ±4.58 p < 0.05
Serum albumin (g/dL) 3.27 ±0.75 2.83 ±1.10 NS
MBP (mmHg) 115.8 ±13.7 100.5 ±15.0 p < 0.05
CCr (mL/minute) 64.0 ±24.1 102.7 ±35.1 p < 0.01
MBP = Mean arterial blood pressure; CCr = 24-hour urinary
creatinine clearance
Table 4.  Comparison of clinical features in adults and children.
Adult Children p value
No. of cases 40 11
Urine protein (g/day) 3.87 ±3.12 3.69 ±1.61 NS
MBP (mmHg) 110.8 ±19.4 96.2 ±17.7 p < 0.05
CCr (mL/minute) 79.1 ±18.9 95.9 ±12.9 p < 0.01
Macroscopic hematuria, no. of cases (%) 5 (12.5%) 6 (54.5%) p = 0.05
Nephrotic syndrome, no. of cases (%) 13 (32.5%) 3 (27.3%) NS
Hypertension, no. of cases (%) 23 (57.5%) 2 (18.2%) p < 0.05
Renal impairment, no. of cases (%) 25 (62.5%) 2 (18.2%) p < 0.05
MBP = Mean arterial blood pressure; CCr = 24-hour urinary creatinine clearance; Hypertension = Blood pressure over 140/90 mmHg; Renal
impairment = CCr < 80 mL/minute
Table 5.  Relationship between renal vascular abnormalities and clinical features.
Vascular abnormalities Present Absent p value
No. of cases 16 28
Urine protein (g/day) 4.16 ±2.02 3.67 ±3.48 NS
MBP (mmHg) 117.8 ±20.9 104.6 ±17.4 p < 0.05
CCr (mL/minute) 62.1 ±33.3 91.2 ±36.7 p < 0.01
Macroscopic hematuria, no. of cases (%) 6 (37.5%) 2 (7.1%) p < 0.05
Microscopic hematuria, no. of cases (%) 12 (75.0%) 11 (39.3%) p < 0.05
Hypertension, no. of cases (%) 13 (81.3%) 10 (35.7%) p < 0.05
Renal impairment, no. of cases (%) 12 (75.0%) 14 (50.0%) NS
Anemia, no. of cases (%) 11 (68.8%) 10 (35.7%) p < 0.05
MBP = Mean arterial blood pressure; CCr = 24-hour urinary creatinine clearance; hypertension = Blood pressure over 140/90 mmHg; Renal
impairment = CCr < 80 mL/minute; Anemia = Hemoglobin < 12.0 g/dL (male) or 11.0 g/dL (female).
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The short- and long-term effects of treatment modality
are shown in table 7 and table 8 respectively. Thirty-
eight of our patients were treated for 8 weeks to 26 years.
There were no significant differences in baseline clinical
features and histology between controlled and treatment
group (details not shown). In general, regimens including
prednisone, with or without anticoagulants, were useful
in reducing proteinuria and improving renal function.
There were no major side effects noted with
immunosuppressive and anticoagulant therapy.
Our patients were followed for an average of 9.5 ±13.1
Table 6.  Relationship between tubulointerstitial abnormalities and clinical features.
Tubulointerstitial abnormalities Mild1 Severe1 p value
No. of cases 28 16
Urine protein (g/day) 3.4 ±3.4 4.7 ±2.0 NS
MBP (mmHg) 102.6 ±20.4 121.3 ±10.7 p < 0.001
CCr (mL/minute) 92.9 ±38.6 58.9 ±25.3 p < 0.005
Hemoglobin (g/dL) 11.6 ±2.0 9.8 ±2.0 p < 0.01
Nephrotic syndrome, no. of cases (%) 10 (35.7%) 13 (81.3%) p < 0.01
Hypertension, no. of cases (%) 8 (28.6%) 15 (93.8%) p < 0.01
Renal impairment, no. of cases (%) 12 (42.9%) 14 (50.0%) p < 0.01
Anemia, no. of cases (%) 10 (35.7%) 11 (68.8%) p < 0.05
MBP = Mean arterial blood pressure; CCr = 24-hour urinary creatinine clearance; Hypertension = Blood pressure over 140/90 mmHg; Renal
impairment = CCr < 80 mL/minute; Anemia = Hemoglobin < 12.0 g/dL (male) or 11.0 g/dL (female).
1See patients and methods for definition.
Table 7.  Effect of therapeutic modalities after 2 months of treatment.
Treatment group
A B C
No. of cases 8 13 25
Decrease in urine protein (% of baseline) 2.4 ±85.0 66.7 ±55.4* 64.7 +60.2*
Decrease in serum creatinine (µmol/L) 10.6 ±8.2 18.6 ±+4.4* 18.0 ±8.4*
Increase in CCr (mL/minute) 5.2 ±13.9 25.0 ±14.9* 26.1 ±9.0*
Decrease in plasma FDP (r/mL) 2.0 ±11.5 3.2 ±9.7 19.1 ±19.0*
Decrease in urinary FDP (r/mL) 2.5 ±3.6 2.6 ±4.2 14.8 ±13.8*
Decrease in plasma fibrinogen (g/dL) 0.0125 ±0.09 0.023 ±0.07 0.16 ±0.14*
Group A = Conservative treatment; Group B = Steroid alone; Group C = Steroid plus anticoagulant; CCr = 24-hour urinary creatinine
clearance; FDP = Fibrin degradation product.
*p < 0.05 when compared with group A.
Table 8. Effect of therapeutic modalities 5 years after treatment.
Treatment group
A B C
No. of cases 8 13 25
Decrease in urine protein (% of baseline) -49.6 ±97.7 42.8 ±40.2* 50.4 ±72.3*
Decrease in serum creatinine (µmol/L) -8.8 ±20.1 10.1 ±17.6* 12.3 ±18.8*
Increase in CCr (mL/minute) -6.4 ±14.6 7.3 ±6.6 * 9.7 ±14.0*
Group A = Conservative treatment; Group B = Steroid alone; Group C = Steroid plus anticoagulant; CCr = 24-hour urinary creatinine
clearance
*p < 0.05 when compared with group A.
years. Five patients progressed to end-stage renal failure,
four other patients died. Most of these patients presented
with nephrotic syndrome, hypertension, or impaired renal
function, and had moderate to severe histopathology
changes. Only four of these nine patients received a short
course of prednisone after diagnosis, while the other five
received no immunosuppressive therapy.
DISCUSSION
MPGN is characterized by diffuse mesangial cells and
matrix proliferation with glomerular capillary wall
thickening. There are three main morphologic categories.
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In the present series, 21 specimens had electron
microscopy classification: 14 were type I MPGN, and
seven were type III MPGN. We did not find any case of
type II MPGN. Clinical features were variable. One-third
of the patients had preceding upper respiratory tract
infection. Clinical features were similar to the report
series (1,7-9). Almost half of our patients had anemia at
presentation that was not explained by the degree of renal
failure. This anemia was possibly related to the presence
of activated complement on the surface of the red cells
(1 ,2) .  Almost  one  ha l f  o f  our  pa t ien ts  had
hypocomplementemia, similar to a previous report (2).
Since many patients with hypocomplementemia had C3
positive in immunofluorescence, it was possible that C3
deposition in glomerulus caused hypocomplementemia.
We found that patients of type I MPGN frequently
presented with hypertension and renal function
impairment, while type III MPGN often presented with
nephrotic syndrome. We found cases of type I MPGN
commonly had crescents, glomerulosclerosis, and serious
tubulointerstitial abnormality, while type III MPGN often
had prominent basement membrane changes and
subepithelial electron-dense deposits. Our observations
were similar to the report of Chen et al (10).
Similar to the report of Cameron (11), children more
frequently presented with macroscopic hematuria. In
general, renal function deteriorates less rapidly in
children than that in adults. However, the outcome of
children is also poor 10 years after initial diagnosis.
Interestingly, in our study, we found that the
histopathology changes of adult MPGN were more
serious than that in children. This is contrary to the
observation by Cameron (11).
In our series, renal vascular lesions can be seen in 16
cases. The changes included arteriole intimal fibrosis and
hyaline degeneration of arteriole. Hematuria,
hypertension, renal function impairment and anemia were
more frequent in patients with renal vascular lesions. This
observation is similar to that by Kincaid-Smith (12).
Tubulointerstitial lesions were also common in our series.
We found that tubulointerstitial abnormalities correlated
closely with the rate of renal function deterioration and
prognosis. Our observations agreed with many other
reports (12,14,15).
In our series, nine patients (17.6%) developed end-stage
renal failure after a median follow-up of 9 years.
Nephrotic syndrome, hypertension, impaired renal func
tion, and presence of crescents, sclerosis, and
tubulointerstitial abnormalities in biopsy specimens were
poor prognostic factors. These observations were similar
 to most reports (11,16,17).
In our study, 13 patients were treated with prednisone
alone, and 25 had prednisone with anticoagulant.
Our data suggested that immunosuppressive and
anticoagulant therapy could reduce proteinuria and slow
the rate of decline of renal function. However, the effect
was apparently not long-lasting. In our series, most
patients discontinued with the treatment at their own will
after initial clinical remission. Only four patients received
steroid for over 6 months. One of them developed end
stage renal disease 16 years after biopsy. The other three
had normal renal function up to 26 years after biopsy.
Cameron suggested that steroid should be maintained at
a low-dose to achieve long-term benefit (18).
In summary, MPGN is an aggressive disease with poor
long-term prognosis. Steroid therapy, with or without
anticoagulants, may have a beneficial effect. However,
the optimal duration of therapy remains to be determined.
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